Dashboard
Manage Tickers

PYXS Pyxis Oncology, Inc.

Nasdaq pyxisoncology.com


$ 3.77 $ 0.43 (13.31 %)    

Wednesday, 15-Oct-2025 19:53:39 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 3.66
$ 3.25
$ 3.70 x 510
$ 3.92 x 200
$ 3.25 - $ 3.68
$ 0.83 - $ 5.39
882,794
na
226.62M
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pyxis-oncology-to-present-translational-data-for-micvotabart-pelidotin-at-upcoming-medical-meetings-findings-demonstrate-micvos-effects-on-tumor-microenvironment-remodeling-and-immune-activation
Pyxis Oncology To Present Translational Da...
10/13/2025 20:09:59

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generati...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
10/06/2025 21:06:27

guggenheim-initiates-coverage-on-pyxis-oncology-with-buy-rating-announces-price-target-of-5
Guggenheim Initiates Coverage On Pyxis Onc...
09/04/2025 13:54:29

Guggenheim analyst Brad Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Targ...

hc-wainwright--co-reiterates-buy-on-pyxis-oncology-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Pyxi...
08/19/2025 11:02:47

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 p...

pyxis-oncology-q2-eps-030-beats-035-estimate-sales-282m
Pyxis Oncology Q2 EPS $(0.30) Beats $(0.35...
08/14/2025 20:36:54

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35...

pyxis-oncology-updates-enrollment-for-phase-1-trial-of-new-cancer-drug-micvo
Pyxis Oncology Updates Enrollment for Phas...
08/04/2025 11:29:11

On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.'s (the "Company") Ph...

hc-wainwright--co-reiterates-buy-on-pyxis-oncology-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Pyxi...
05/19/2025 10:55:33

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 p...

pyxis-oncology-q1-eps-035-misses-029-estimate
Pyxis Oncology Q1 EPS $(0.35) Misses $(0.2...
05/15/2025 11:10:59

pyxis-oncology-announces-robust-preclinical-data-supporting-unique-extracellular-linker-payload-cleaving-mechanism-of-action-of-micvotabart-pelidotin-and-validating-micvos-ongoing-clinical-development
Pyxis Oncology Announces Robust Preclinica...
04/25/2025 17:20:38

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identif...

pyxis-oncology-will-present-new-preclinical-data-supporting-development-of-first-in-concept-antibody-drug-conjugate-targeting-edbfn-in-tumor-microenvironment-at-aacr-2025
Pyxis Oncology Will Present New Preclinica...
03/25/2025 20:32:51

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat can...

pyxis-oncology-to-present-preclinical-data-on-potential-of-pyx-201-at-aacr-2025-apr-28
Pyxis Oncology To Present Preclinical Data...
03/25/2025 20:31:21

rbc-capital-reiterates-outperform-on-pyxis-oncology-maintains-8-price-target
RBC Capital Reiterates Outperform on Pyxis...
03/19/2025 14:44:15

RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and maintains $8 price target.

hc-wainwright--co-reiterates-buy-on-pyxis-oncology-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Pyxi...
03/19/2025 10:37:50

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 p...

as-of-december-31-2024-pyxis-oncology-had-cash-and-cash-equivalents-of-1284m-that-is-expected-to-provide-cash-runway-into-the-second-half-of-2026
As Of December 31, 2024, Pyxis Oncology Ha...
03/18/2025 11:34:29

pyxis-oncology-fy-2024-gaap-eps-132-misses-109-estimate-sales-1615m-beat-1381m-estimate
Pyxis Oncology FY 2024 GAAP EPS $(1.32) Mi...
03/18/2025 11:33:04

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1....

pyxis-oncology-granted-fda-fast-track-designation-for-pyx-201-monotherapy-in-recurrent-or-metastatic-head-and-neck-cancer
Pyxis Oncology Granted FDA Fast Track Desi...
02/26/2025 12:31:26

pyxis-oncology-initiates-phase-12-combination-trial-of-pyx-201-with-keytruda
Pyxis Oncology Initiates Phase 1/2 Combina...
02/04/2025 12:36:56

pyxis-oncologys-deprioritizes-second-pipeline-asset-analyst-applauds-move
Pyxis Oncology's Deprioritizes Second Pipe...
12/20/2024 16:13:53

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource...

hc-wainwright--co-reiterates-buy-on-pyxis-oncology-lowers-price-target-to-5
HC Wainwright & Co. Reiterates Buy on Pyxi...
12/20/2024 15:55:53

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and lowers the pri...

rbc-capital-reiterates-outperform-on-pyxis-oncology-lowers-price-target-to-8
RBC Capital Reiterates Outperform on Pyxis...
12/20/2024 14:57:31

RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target fr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION